公开(公告)号：US09458555B2

公开(公告)日：2016-10-04

申请号：US12687044

申请日：2010-01-13

Applicant: Chung-Hsuan Chen ,  Chen-Ren Hsiao

Inventor： Chung-Hsuan Chen ,  Chen-Ren Hsiao

IPC: C12M1/34 ,  C12M3/00 ,  C12Q1/68 ,  G01N33/53 ,  C12P19/34 ,  C07H21/02 ,  C07H21/04 ,  A61K38/00 ,  C07K1/00 ,  C40B30/04 ,  G01N33/58

CPC classification number: C40B30/04 ,  G01N33/587

Abstract: Methods for determining the quality of a biomolecular microarray to determine suitability of the microarray for performing specific binding reactions, such as hybridization, are provided. Methods are based on staining a microarray with a solution of detectable nanoparticles that reversibly stain the biomolecules through an electrostatic interaction to select microarrays that meet quality standards for hybridization reactions. A gold nanoparticle solution based staining method for DNA microarrays is provided. Destaining methods allowing multiple rounds of hybridization of nanogold stained microarrays are provided. Microarrays selected by methods of the invention are provided.

Abstract translation: 提供了用于确定生物分子微阵列的质量以确定用于进行特异性结合反应（例如杂交）的微阵列适合性的方法。 方法是基于用可检测纳米颗粒的溶液染色微阵列，其通过静电相互作用可逆地染色生物分子，以选择满足杂交反应质量标准的微阵列。 提供了一种基于金纳米颗粒溶液的DNA微阵列染色方法。 提供了允许纳米金染色的微阵列进行多轮杂交的脱色方法。 提供了通过本发明的方法选择的微阵列。

公开(公告)号：US20160237509A1

公开(公告)日：2016-08-18

申请号：US15027032

申请日：2014-10-01

Applicant: Academia Sinica

Inventor： Ting-Fang Wang

IPC: C12Q1/68 ,  C12N1/14

CPC classification number: C12Q1/6895 ,  C12N1/14

Abstract: The present invention relates to a technology to provide segmental aneuploidy progeny strains of Trichoderma reesei. In particular, the present invention relates to a method to produce segmental aneuploidy progeny strains of Trichoderma reesei via sexual crossing of two parent haploid strains with chromosome heterozygosity (e.g. one having scaffold M and scaffold 33, the other having scaffold F and scaffold X), preferably at least one of which includes a non-homologous end joining (NHEJ) gene. The present invention also relates to stable, segmental aneuploidy progeny strains of richoderma reesei thus produced which particularly exhibit enhanced gene expression or activities of carbohydrate-active enzymes (CAZymes) and more particularly prevent returning to euploidy for an extended period of time.

Abstract translation: 本发明涉及一种提供里氏木霉的片段非整倍体后代菌株的技术。 特别地，本发明涉及通过两个亲本单倍体菌株与染色体杂合性（例如具有支架M和支架33，另一个具有支架F和支架X）的性交叉产生里氏木霉的节段非整倍体后代菌株的方法， 优选其中至少一个包括非同源末端连接（NHEJ）基因。 本发明还涉及如此制备的里氏木霉的稳定的，非段落的非整倍体后代，其特别表现出增强的碳水化合物活性酶（CAZymes）的基因表达或活性，更特别地防止长时间地恢复整倍体。

公开(公告)号：US09411649B2

公开(公告)日：2016-08-09

申请号：US14320661

申请日：2014-07-01

Applicant: National Taiwan University ,  Academia Sinica

Inventor： Po-Hsien Tseng ,  Pi-Cheng Hsiu ,  Chin-Chiang Pan ,  Tei-Wei Kuo ,  Wei-Ming Chen

IPC: G06F9/46 ,  G06F9/50 ,  G06F9/48

CPC classification number: G06F9/5011 ,  G06F9/4881 ,  G06F9/50 ,  G06F9/5088 ,  G06F2209/501 ,  Y02D10/32

Abstract: A resource allocation method adapted to a mobile device having a multi-core central processing unit (CPU) is provided. The CPU executes at least one application. The method includes steps as follows. A usage status of each of the at least one application is obtained according to a level of concern of a user for each of the at least one application. A sensitivity of at least one thread of each of the at least one application is determined according to the usage status of each of the at least one application. Resources of the CPU are allocated according to the sensitivity of the at least one thread run by the cores.

Abstract translation: 提供了一种适用于具有多核心中央处理单元（CPU）的移动设备的资源分配方法。 CPU至少执行一个应用程序。 该方法包括以下步骤。 根据用户对于至少一个应用中的每一个的关注程度，获得至少一个应用中的每一个的使用状态。 根据所述至少一个应用中的每一个的使用状态来确定所述至少一个应用中的每一个的至少一个线程的灵敏度。 根据由核心运行的至少一个线程的灵敏度来分配CPU的资源。

公开(公告)号：US09387257B2

公开(公告)日：2016-07-12

申请号：US14599291

申请日：2015-01-16

Applicant: Academia Sinica

Inventor： Han-Chung Wu ,  Yi-Hsuan Chi

IPC: A61K38/16 ,  C07K5/00 ,  A61K47/48 ,  A61K31/704 ,  G01N33/574

CPC classification number: A61K47/48246 ,  A61K31/704 ,  A61K47/48815 ,  A61K47/64 ,  A61K47/6911 ,  G01N33/57423 ,  G01N2458/00

Abstract: A conjugate is disclosed. The conjugate comprises (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-8; and (b) a component conjugated to the targeting peptide, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, a liposome, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. Methods of treating lung cancer and detecting lung cancer cells are also disclosed.

Abstract translation: 公开了缀合物。 缀合物包含（a）长度小于15个氨基酸残基的分离或合成的靶向肽，其包含与选自SEQ ID NO：1-8的序列具有至少90％同一性的氨基酸序列 ; 和（b）与靶向肽缀合的组分，该组分选自药物递送载体，抗癌药物，胶束，纳米颗粒，脂质体，聚合物，脂质，寡核苷酸， 肽，多肽，蛋白质，细胞，成像剂和标记试剂。 还公开了治疗肺癌和检测肺癌细胞的方法。

公开(公告)号：US09382330B2

公开(公告)日：2016-07-05

申请号：US13103845

申请日：2011-05-09

Applicant: Wen-Ching Yang

Inventor： Wen-Ching Yang

IPC: A61K31/704 ,  C07K16/40 ,  A61K31/00 ,  A61K31/337 ,  A61K31/36 ,  A61K31/4188 ,  A61K31/713 ,  A61K38/12 ,  A61K45/06 ,  G01N33/574

CPC classification number: C07K16/40 ,  A61K31/00 ,  A61K31/337 ,  A61K31/36 ,  A61K31/4188 ,  A61K31/704 ,  A61K31/713 ,  A61K38/12 ,  A61K45/06 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2333/99 ,  A61K2300/00

Abstract: Methods of diagnosing cancer that are based in part on the findings that Pdia4 promotes cell growth, cell proliferation, and cell cycle are disclosed herein. Methods of using microvessel density as a surrogate marker and reducing tumor microvessel density in a subject are also enclosed herein.

Abstract translation: 本文公开了部分基于Pdia4促进细胞生长，细胞增殖和细胞周期的发现的诊断癌症的方法。 本文还包括使用微血管密度作为替代标志物并降低受试者的肿瘤微血管密度的方法。

公开(公告)号：US20160177329A1

公开(公告)日：2016-06-23

申请号：US14828842

申请日：2015-08-18

Applicant: Academia Sinica

Inventor： Tuan-hua David Ho ,  Wan-chi Lin ,  Kuan-Ying Huang

IPC: C12N15/82

CPC classification number: C12N15/8267

Abstract: The present invention relates to a method for inhibiting sprouting, particularly pre-harvest sprouting, in plant seeds, by introducing a polynucleotide encoding a FCA protein into the plant.

Abstract translation: 本发明涉及通过将编码FCA蛋白质的多核苷酸引入植物中来抑制种子发芽，特别是收获前发芽的方法。

公开(公告)号：US20160160231A1

公开(公告)日：2016-06-09

申请号：US14960915

申请日：2015-12-07

Applicant: Academia Sinica

Inventor： SU-MAY YU ,  Tuan-Hua David Ho ,  Shuen-Fang Lo ,  Ching-Yi Liao

IPC: C12N15/82 ,  C07K14/415

CPC classification number: C12N15/8273 ,  C07K14/415 ,  C12N15/8261 ,  Y02A40/146

Abstract: Transgenic plants that over-express a Big Grain 2 (BG2) gene and methods of using such for improving the growth, productivity, or stress tolerance of a plant.

Abstract translation: 过表达大颗粒2（BG2）基因的转基因植物及其用于改善植物的生长，生产力或胁迫耐受性的方法。

公开(公告)号：US09353422B2

公开(公告)日：2016-05-31

申请号：US14405085

申请日：2013-05-31

Applicant: Hsiu-Ming Shih ,  Wei-Chih Yang

Inventor： Hsiu-Ming Shih ,  Wei-Chih Yang

IPC: C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  C12N15/113 ,  G01N33/50

CPC classification number: C12Q1/6897 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q2600/136 ,  G01N33/5008 ,  G01N2333/948 ,  G01N2500/10

Abstract: Method of regulating the stability and/or the level of the fusion protein PLZF/RARA are disclosed. Also disclosed are methods for identifying an agent as a regulator of the stability and/or the level of the fusion protein PLZF/RARA. Methods for identifying a therapeutic agent for treating PLZF/RARA-associated acute promyelocytic leukemia (APL) is also disclosed.

Abstract translation: 公开了调节融合蛋白PLZF / RARA的稳定性和/或水平的方法。 还公开了用于鉴定作为融合蛋白PLZF / RARA的稳定性和/或水平的调节剂的试剂的方法。 还公开了用于鉴定治疗PLZF / RARA相关急性早幼粒细胞白血病（APL）的治疗剂的方法。

公开(公告)号：US09353061B2

公开(公告)日：2016-05-31

申请号：US14416051

申请日：2013-07-19

Applicant: Academia Sinica ,  National Taiwan University

Inventor： Jung-Hsin Lin ,  Jim-Min Fang ,  Ting-Rong Chern ,  Jhih-Bin Chen ,  Ching-Chow Chen ,  Tzu-Tang Wei

IPC: A61K31/221 ,  C07D215/14 ,  C07C259/08 ,  A61K31/401 ,  A61K31/4045 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K45/06 ,  C07C259/06 ,  C07D207/34 ,  C07D209/24 ,  C07D213/56 ,  C07D239/42

CPC classification number: C07D215/14 ,  A61K31/221 ,  A61K31/401 ,  A61K31/4045 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K45/06 ,  C07B2200/07 ,  C07C259/06 ,  C07C259/08 ,  C07C2602/28 ,  C07D207/34 ,  C07D209/24 ,  C07D213/56 ,  C07D239/42

Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.

Abstract translation: 本发明提供新的式（I）化合物及其药物组合物。 式（I）化合物是组蛋白脱乙酰酶（HDAC）和3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶（HMGR）的抑制剂。 还提供了使用化合物和药物组合物来抑制HDAC和HMGR的活性，治疗与HDAC或HMGR相关的疾病（例如癌症，高胆固醇血症，急性或慢性炎性疾病，自身免疫性疾病，过敏性疾病，病原体感染， 神经变性疾病和与氧化应激相关的疾病），或抑制癌细胞的耐药性。

公开(公告)号：US20160145625A1

公开(公告)日：2016-05-26

申请号：US14760904

申请日：2014-01-14

Applicant: DCB-USA LLC ,  NATIONAL TAIWAN UNIVERSITY ,  Academia Sinica

Inventor： Pan-Chyr Yang ,  Wei-Yun Lai ,  Konan Peck

IPC: C12N15/113 ,  A61K31/713 ,  A61K31/517

CPC classification number: C12N15/1138 ,  A61K31/517 ,  A61K31/713 ,  C07K14/485 ,  C12N2310/127 ,  C12N2310/315 ,  C12N2310/33 ,  C12N2310/3515 ,  C12N2320/31 ,  C12N2320/34

Abstract: The invention provides DNAzymes which are capable to silence the expression of EGFR at allele-specific level. These allele-specific DNAzymes against EGFR T790M mutation will knockdown the expression of EGFR T790M mRNA while keeping EGFR wild-type mRNA intact. Hence, these allele-specific DNAzymes against EGFR T790M mutation may overcome T790M-derived TKI resistance accompanied with lower unwanted side effects on normal cells in lung cancer patients.

Abstract translation: 本发明提供能够使等位基因特异性水平的EGFR表达沉默的DNA酶。 针对EGFR T790M突变的这些等位基因特异性DNA酶将会破坏EGFR T790M mRNA的表达，同时保持EGFR野生型mRNA的完整性。 因此，针对EGFR T790M突变的这些等位基因特异性DNA酶可以克服T790M衍生的TKI抗性，伴随着对肺癌患者正常细胞的不希望的副作用。